However, it was not observed in subgroups of patients treated with anti‐CD20 or BTKI, a higher risk of developing symptomatic COVID‐19, compared to all other treatment regimens (p = 0.78 and 0.886, respectively) (Table S8). This evidence concerns the gene IBTK and COVID-19.